Literature DB >> 26802537

Viral vector mediated continuous expression of interleukin-10 in DRG alleviates pain in type 1 diabetic animals.

Vikram Thakur1, Mayra Gonzalez1, Kristen Pennington1, Munmun Chattopadhyay2.   

Abstract

Painful diabetic neuropathy is a common and difficult to treat complication of diabetes. A growing body of evidence implicates the role of inflammatory mediators in the damage to the peripheral axons and in the pathogenesis of neuropathic pain. Increased expression of pro-inflammatory cytokines such as interleukin (IL)-1β and tumor necrosis factor (TNF)-α in the peripheral nervous system suggests the possibility of change in pain perception in diabetes. In this study we investigated that continuous delivery of IL10 in the nerve fibers achieved by HSV vector mediated transduction of dorsal root ganglion (DRG) in animals with Type 1 diabetes, blocks the nociceptive and stress responses in the DRG neurons by reducing IL1β expression along with inhibition of phosphorylation of p38 MAPK (mitogen-activated protein kinase) and protein kinase C (PKC). The continuous expression of IL10 also alters Toll like receptor (TLR)-4 expression in the DRG with increased expression of heat shock protein (HSP)-70 in conjunction with the reduction of pain. Taken together, this study suggests that macrophage activation in the peripheral nervous system may be involved in the pathogenesis of pain in Type 1 diabetes and therapeutic benefits of HSV mediated local expression of IL10 in the DRG with the reduction of a number of proinflammatory cytokines, subsequently inhibits the development of painful neuropathy along with a decrease in stress associated markers in the DRG. This basic and preclinical study provides an important evidence for a novel treatment strategy that could lead to a clinical trial for what is currently a treatment resistant complication of diabetes.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DRG; Diabetic neuropathy; Gene therapy; Inflammation, TLR4; Interleukin-10; Pain

Mesh:

Substances:

Year:  2016        PMID: 26802537     DOI: 10.1016/j.mcn.2016.01.006

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  10 in total

Review 1.  Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.

Authors:  Nebojsa Nick Knezevic; Ajay Yekkirala; Tony L Yaksh
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

Review 2.  The crosstalk among TLR2, TLR4 and pathogenic pathways; a treasure trove for treatment of diabetic neuropathy.

Authors:  Seyed Hossein Aghamiri; Khalil Komlakh; Mehran Ghaffari
Journal:  Inflammopharmacology       Date:  2022-01-12       Impact factor: 4.473

3.  Nanotechnology for Pain Management: Current and Future Therapeutic Interventions.

Authors:  Divya Bhansali; Shavonne L Teng; Caleb S Lee; Brian L Schmidt; Nigel W Bunnett; Kam W Leong
Journal:  Nano Today       Date:  2021-06-19       Impact factor: 18.962

4.  Interactions of Notch1 and TLR4 signaling pathways in DRG neurons of in vivo and in vitro models of diabetic neuropathy.

Authors:  Tianhua Chen; Hao Li; Yiting Yin; Yuanpin Zhang; Zhen Liu; Huaxiang Liu
Journal:  Sci Rep       Date:  2017-11-02       Impact factor: 4.379

5.  Low GRK2 Underlies Hyperalgesic Priming by Glial Cell-Derived Neurotrophic Factor.

Authors:  Hui-Jing Wang; Han-Xin Gu; Niels Eijkelkamp; Cobi J Heijnen; Annemieke Kavelaars
Journal:  Front Pharmacol       Date:  2018-06-05       Impact factor: 5.810

Review 6.  Viral Vectors in Gene Therapy.

Authors:  Kenneth Lundstrom
Journal:  Diseases       Date:  2018-05-21

Review 7.  Can FDA-Approved Immunomodulatory Drugs be Repurposed/Repositioned to Alleviate Chronic Pain?

Authors:  Kufreobong E Inyang; Joseph K Folger; Geoffroy Laumet
Journal:  J Neuroimmune Pharmacol       Date:  2021-05-26       Impact factor: 4.147

8.  Tanshinone IIA Attenuates Diabetic Peripheral Neuropathic Pain in Experimental Rats via Inhibiting Inflammation.

Authors:  Baojian Zhang; Yanbing Yu; Gele Aori; Qi Wang; Dawei Kong; Wenqiang Yang; Zhuangli Guo; Li Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-11       Impact factor: 2.629

Review 9.  Redefining distal symmetrical polyneuropathy features in type 1 diabetes: a systematic review.

Authors:  Eleonora Galosi; Xiaoli Hu; Nivatha Michael; Jens Randel Nyengaard; Andrea Truini; Páll Karlsson
Journal:  Acta Diabetol       Date:  2021-07-02       Impact factor: 4.280

10.  Spinal microglial β-endorphin signaling mediates IL-10 and exenatide-induced inhibition of synaptic plasticity in neuropathic pain.

Authors:  Le Ma; Shiyu Peng; Jinbao Wei; Mengjing Zhao; Khalil Ali Ahmad; Jinghong Chen; Yong-Xiang Wang
Journal:  CNS Neurosci Ther       Date:  2021-06-10       Impact factor: 5.243

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.